Overview
- Legal name
- A&G PHARMACEUTICAL, INC.
- Also known as
- A & G PHARMACEUTICAL INC
- Registered location
- COLUMBIA, MD, USA
- Website
- Company website ↗
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- Latest award activity
- Aug 26, 2026
Read company summary
A&G PHARMACEUTICAL, INC. is associated with UEI SN6SWFABJXL1 and CAGE 1T9L5 in public federal records. AcornBids currently links 7 prime awards totaling $254.4K in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology); Research and Development in Biotechnology (except Nanobiotechnology); Biological Product (except Diagnostic) Manufacturing. These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Its public SAM.gov registration lists COLUMBIA, MD, USA.
At a glance
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 15, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- A&G PHARMACEUTICAL, INC.
- Doing business as
- A & G PHARMACEUTICAL INC
- UEI
- SN6SWFABJXL1
- CAGE
- 1T9L5
- Registered address
- 9130 RED BRANCH RD STE U, COLUMBIA, MD, 21045, USA
- Registration status
- Active
- Primary NAICS
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- SAM activation
- Oct 15, 2025
- Initial registration
- Jun 8, 2001
- Entity start
- Jun 6, 2000
- SAM updated
- Oct 15, 2025
- Registration expires
- Oct 13, 2026
- Fiscal year end
- Dec 31
- Place of incorporation
- DE, USA
Research brief
Source facts
- Loaded prime-award records link 7 awards and $254,420 in reported obligations to this legal entity. Source
- Recorded awards include Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (NAICS 541715); this classification is not proof of every company capability. Source
- An example award describes: ANTIBODY DEVELOPMENT SERVICES FOR MALARIAL ORGANELLES Source
Federal award analysis
Net transaction obligations by federal fiscal period.
Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 7 of 7 selected awards. Select a period to explore its awards.
Funding change
Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.
| Measure | Reported value |
|---|---|
| Current period | Oct 1, 2025 – Sep 30, 2026 |
| Current obligations | $-27.7K |
| Prior period | Oct 1, 2024 – Sep 30, 2025 |
| Prior obligations | $24.9K |
| Change | $-52.6K |
| Growth | -211.3% |
Where the work is performed
State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.
Agencies
| Category | Period obligations | Awards |
|---|---|---|
| Department of Health and Human Services | $144.6K | 7 |
Offices
| Category | Period obligations | Awards |
|---|---|---|
| NATIONAL INSTITUTES OF HEALTH NIDA | $104.2K | 2 |
| NATIONAL INSTITUTES OF HEALTH NIAID | $32.4K | 3 |
| NATIONAL INSTITUTES OF HEALTH NCATS | $13.6K | 1 |
| NIH NCI | $-5.6K | 1 |
Naics
Psc
| Category | Period obligations | Awards |
|---|---|---|
| AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $104.2K | 2 |
| Q301 — Reference Laboratory Testing | $29.1K | 3 |
| 6505 — Drugs and Biologicals | $16.9K | 1 |
| 6640 — Laboratory Equipment and Supplies | $-5.6K | 1 |
Vehicles
| Category | Period obligations | Awards |
|---|---|---|
| 75N95018D00010 | $104.2K | 2 |
| Unclassified | $40.4K | 5 |
States
| Category | Period obligations | Awards |
|---|---|---|
| MD | $144.6K | 7 |
Set Asides
| Category | Period obligations | Awards |
|---|---|---|
| Unclassified | $104.2K | 2 |
| NO SET ASIDE USED. | $40.4K | 5 |
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75N93021P01162ANTIBODY DEVELOPMENT SERVICES FOR MALARIAL ORGANELLES | Department of Health and Human Services | $0 | Aug 16, 2021 | Dec 31, 2021 |
| 75N95022F00001POLYCLONAL RAT ANTIBODY AND MONOCLONAL RAT ANTIBODIES AGAINST GLYCOL-CHITOSAN NANOPARTICLES | Department of Health and Human Services | $83.4K | Jun 30, 2022 | Mar 31, 2025 |
| 75N93024P01059PRECISION ANTIBODY (AMBIS #2229539) LAB TESTING, FUSION, CLONING | Department of Health and Human Services | $15.5K | Aug 27, 2024 | Nov 30, 2024 |
| 75N95C25P00114TO GENERATE REAGENTS AGAINST AZM-152, A DRUG CANDIDATE FROM TDB AZOME PROJECT. | Department of Health and Human Services | $13.6K | Sep 24, 2025 | Sep 23, 2026 |
| 75N93025P00729MONOCLONAL ANTIBODY AGAINST MARCH1 PREPARATION MAB-P3-00-001, 002, 003, 005 AND MAB-P3-HC-001 (AMBIS #2254762) | Department of Health and Human Services | $16.9K | Mar 25, 2025 | Jul 31, 2025 |
| 75N91020P00499NIH-APPROVED COVID-RELATED PROJECT: ANALYSIS OF A NOVEL TRUNCATED FORM OF ACE2 RECEPTOR | Department of Health and Human Services | $19.3K | Jun 18, 2020 | Jun 19, 2020 |
| 75N95024F00001TASK ORDER 7 - DOK7 | Department of Health and Human Services | $105.7K | Mar 18, 2024 | Mar 17, 2025 |
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Oct 15, 2025 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Jun 8, 2001 |
| Entity start | Jun 6, 2000 |
Registration classifications: Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 325412 — Pharmaceutical Preparation Manufacturing | Not reported |
| 325413 — In-Vitro Diagnostic Substance Manufacturing | Not reported |
| 541690 — Other Scientific and Technical Consulting Services | Not reported |
| 541714 — Research and Development in Biotechnology (except Nanobiotechnology) | Not reported |
| 621511 — Medical Laboratories | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| GINETTE SERRERO | Government business | Contact method not published | SAM registration | Not available |
| STEPHANIE MURCEK | Alternate government business | Contact method not published | SAM registration | Not available |
| GINETTE SERRERO | Electronic business | Contact method not published | SAM registration | Not available |
| STEPHANIE MURCEK | Alternate electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 325412 — Pharmaceutical Preparation Manufacturing
- 325413 — In-Vitro Diagnostic Substance Manufacturing
- 541690 — Other Scientific and Technical Consulting Services
- 541714 — Research and Development in Biotechnology (except Nanobiotechnology)
- 621511 — Medical Laboratories
Registered products and services
- 6505 — Drugs and Biologicals
- 6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
- AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- AN22 — HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH
- B504 — Chemical/Biological Studies and Analysis
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit